阿里尔碳化合物受体激活对炎症性肠道疾病的肠道微生物组相关的抗炎作用
Salvinaz Islam Moutusy1,2,3, Seiichiroh Ohsako1
1Laboratory of Environmental Health Sciences, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.
International journal of molecular sciences
|March 28, 2024
概括
炎症性肠病 (IBD) 涉及与微生物失衡相关的肠道炎症. 用肠道细菌激活烯碳水化合物受体 (AHR) 对IBD治疗有希望.
科学领域:
- 胃肠道学和免疫学
- 微生物组研究 微生物组研究
- T细胞的分化过程
背景情况:
- 炎症性肠病 (IBD) 是一种常见的慢性胃肠道炎症.
- 肠道微生物组,细胞因子平衡,基碳化合物受体 (AHR) 和T助手 (Th) 细胞分化是IBD免疫病理学的关键.
- AHR的激活取决于调控和效应T细胞平衡,这对于预防肠道失调和炎症至关重要.
研究的目的:
- 审查最近的进展,了解由IBD开始性肠道细菌激活AHR的好处.
- 在IBD中建立AHR介导的治疗策略的概念框架.
- 突出肠道微生物组和AHR信号在IBD病变发生过程中的相互作用.
主要方法:
- 关于IBD,肠道微生物组和AHR信号的最新研究的文献综述.
- 分析连接共生细菌,AHR激活和肠道免疫反应的机制.
- 综合当前的知识,开发治疗干预的概念框架.
主要成果:
- 结肠肠道细菌在调节AHR活动中起着至关重要的作用.
- 微生物代谢物的AHR激活可以促进免疫耐受性并减少肠道炎症.
- 在IBD中,失生症会破坏由AHR介导的有益信号通路.
结论:
- 通过开始性肠道细菌准AHR激活是IBD的有希望的治疗途径.
- 恢复微生物平衡和增强AHR信号可能会缓解肠道炎症.
- 对微生物组-AHR轴的进一步研究对于开发新的IBD干预措施至关重要.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331


